Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer.
Repository Usage Stats
INTRODUCTION: : We evaluated treatment patterns of elderly patients with stage IIIA (N2) non-small-cell lung cancer (NSCLC). METHODS: : The use of surgery, chemotherapy, and radiation for patients with stage IIIA (T1-T3N2M0) NSCLC in the Surveillance, Epidemiology, and End Results-Medicare database from 2004 to 2007 was analyzed. Treatment variability was assessed using a multivariable logistic regression model that included treatment, patient, tumor, and census track variables. Overall survival was analyzed using the Kaplan-Meier approach and Cox proportional hazard models. RESULTS: : The most common treatments for 2958 patients with stage IIIA (N2) NSCLC were radiation with chemotherapy (n = 1065, 36%), no treatment (n = 534, 18%), and radiation alone (n = 383, 13%). Surgery was performed in 709 patients (24%): 235 patients (8%) had surgery alone, 40 patients (1%) had surgery with radiation, 222 patients had surgery with chemotherapy (8%), and 212 patients (7%) had surgery, chemotherapy, and radiation. Younger age (p < 0.0001), lower T-status (p < 0.0001), female sex (p = 0.04), and living in a census track with a higher median income (p = 0.03) predicted surgery use. Older age (p < 0.0001) was the only factor that predicted that patients did not get any therapy. The 3-year overall survival was 21.8 ± 1.5% for all patients, 42.1 ± 3.8% for patients that had surgery, and 15.4 ± 1.5% for patients that did not have surgery. Increasing age, higher T-stage and Charlson Comorbidity Index, and not having surgery, radiation, or chemotherapy were all risk factors for worse survival (all p values < 0.001). CONCLUSIONS: : Treatment of elderly patients with stage IIIA (N2) NSCLC is highly variable and varies not only with specific patient and tumor characteristics but also with regional income level.
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
Combined Modality Therapy
Published Version (Please cite this version)10.1097/JTO.0b013e31828916aa
Publication InfoBerry, Mark Francis; Worni, Mathias; Pietrobon, Ricardo Santos; D'Amico, Thomas Anthony; & Akushevich, Igor (2013). Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer. J Thorac Oncol, 8(6). pp. 744-752. 10.1097/JTO.0b013e31828916aa. Retrieved from https://hdl.handle.net/10161/14834.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Associate Research Professor in the Social Science Research Institute
Gary Hock Professor of Surgery
Lung Cancer 1.Role of molecular markers in the prognosis and therapy of lung cancer 2.Genomic analysis lung cancer mutations Esophageal Cancer 1.Role of molecular markers in the prognosis and therapy of esophageal cancer 2.Genomic analysis esophageal cancer mutations
Medical Instructor in the Department of Surgery
This author no longer has a Scholars@Duke profile, so the information shown here reflects their Duke status at the time this item was deposited.
Alphabetical list of authors with Scholars@Duke profiles.